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Epilepsy is one of the most prevalent chronic neurological conditions affecting approximately 0.5–2% of the
population worldwide [1]. Patients with epilepsy repeatedly and unexpectedly experience sudden changes in behavior
and or consciousness. Epileptic discharges can involve only a part of the brain, causing focal seizures, or the entire
brain leading to generalized seizures. First-line treatment comprises pharmacotherapy with one or more anti-
epileptic drugs. Several anti-epileptic drugs are currently available with distinct mechanisms of action and side
effects. However, for an estimated third of epilepsy patients, seizures remain poorly controlled despite optimal
medical management. After failure of at least two anti-epileptic drugs, patients suffer from drug-resistant epilepsy.
For these patients, dedicated diagnostic workup in a specialized epilepsy center is warranted and other treatment
options should be explored. The most effective treatment option for patients with refractory epilepsy is epilepsy
surgery. Following a thorough presurgical evaluation, seizure freedom is obtained in approximately two thirds
of patients with mesial temporal lobe epilepsy and half of patients with focal neocortical epilepsy [2]. Patients
who are considered unsuitable surgery candidates should be considered for neurostimulation. Several types of
neurostimulation have been developed including vagus nerve stimulation (VNS), deep brain stimulation and
responsive neurostimulation. Availability may differ by region. Noninvasive neurostimulation techniques are also
on the rise, aiming to avoid an invasive procedure and accompanying side effects.
Invasive VNS is a neurostimulation therapy which activates vagal nerve fibers in the neck region by means of a
helical electrode that is wound around the cervical vagus nerve and is then connected with a lead to a subclavicularly
implanted pulse generator. In 1997, it was approved by the US FDA as an adjunctive treatment for drug-resistant
epilepsy. The mechanism of action of VNS remains to be fully elucidated. Several lines of evidence support that
VNS induces a norepinephrine release in the hippocampus and cerebral cortex through the vagus nerve–locus
coeruleus system leading to its seizure-suppressing effect [3,4].
The efficacy and safety of VNS have been extensively investigated by several multicenter randomized controlled
trials. During the short-term follow-up of the blinded phase of the randomized trials, seizure frequency was reduced
with 30% with a responder rate (proportion of patients with ≥50% seizure frequency reduction) of 38% [5]. In
the open label extension phase, efficacy further increased to 55% seizure frequency reduction after approximately
5 years of treatment with a responder rate of 63% [6,7]. After 10 years of treatment, seizure frequency reductions
of up to 75% have been reported [8]. These results lead to the current consensus on efficacy that after long-term
treatment up to two thirds of patients have a considerable improvement in seizure control with a reduction in
seizure frequency of at least 50%, when VNS is part of their best medical practice for drug-resistant epilepsy. In
up to a third of patients little or no effect is observed on seizure frequency, but positive effects on mood and
alertness may be present, irrespective of seizure control. Seizure freedom is obtained in less than 10% of patients.
These results show that the individual response to VNS is variable, indicating the need for predictors to identify
VNS responders before implantation, thereby avoiding the risks and costs of an unnecessary surgical procedure.
Few cost–benefit data are currently available. Results show that VNS leads to a positive cost-beneficial balance
mainly due to a significant reduction in hospital admissions, emergency room visits [9] and positive effects on
status epilepticus occurrences [10]. The most frequently reported side effects are hoarseness and voice change during
stimulation and ramping up of the therapy [6]. Outcome and side-effect profile are similar in adults and children.
Over the years, various VNS devices have been developed aiming to improve efficacy and safety. The first devices
delivered stimulation in an open loop fashion with intermittent stimulation of the vagus nerve in cycles of ON
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and OFF periods. On top of this standard stimulation mode, the therapy also comprised a magnet feature allowing
patient or caregivers to administer an additional stimulation at the time of a perceived seizure by passing the magnet
across the pulse generator. Studies have demonstrated the added benefit of this magnet feature [11], but unfortunately
manual use of the magnet is often challenging for patients due to seizure symptoms, nocturnal seizures or cognitive
or physical impairments. To overcome this issue, a new VNS device, the AspireSR R©, with a seizure detection
algorithm automatically triggering stimulation has been developed. The device contains a cardiac-based seizure
detection algorithm that detects ictal heart rate increases and triggers stimulation if the heart rate increase exceeds
a selected threshold. The European E-36 study by Boon et al. and the parallel US E-37 study by Fisher et al.
prospectively evaluated the performance and safety of this new approach. Both studies showed a high sensitivity
for seizure detection with an acceptable false-positive rate. The reduction in seizure frequency was comparable
to open-loop VNS, with responder rates of 30–50% and significant improvements in quality of life [11,12]. A
recent retrospective study by Hamilton et al. showed a higher responder rate of 59% for new implantations with
the AspireSR VNS system and also found improvement sooner in the course of follow-up compared with the
traditional VNS devices. In addition, they found that 71% of patients with a battery change from the previous
models to the AspireSR device reported an additional improvement in seizure control, indicating that this seizure
detection algorithm improves the number of responders [13]. It is expected that this automatic stimulation feature
will be of most benefit to patients with ictal tachycardia who are unable to use the magnet mode. However, further
research will be needed to validate the additional benefit and cost efficacy of this stimulation mode.
The most recently developed VNS device, the SenTiva™ VNS system also contains the cardiac-based seizure
detection algorithm as well as new programming options, aiming to make the use of the device more convenient
for both physicians and patients. It has a more compact size which is particularly beneficial to the growing pediatric
population considered for VNS. The device delivers novel modes of stimulation such as burst stimulation. Two
small preclinical trials suggest that burst stimulation is more effective than regular stimulation, promoting further
research to the anti-epileptic effect of microburst VNS in humans [14,15].
Over the last years, several noninvasive VNS devices have been developed aiming to achieve the same effects as
invasive VNS but without the need for an invasive procedure. Regarding the treatment of refractory epilepsy, most
research has been conducted with transcutaneous auricular VNS. This noninvasive neurostimulation modality
stimulates the cutaneous receptive field of the auricular branch of the vagus nerve in the outer ear. It has been
demonstrated with functional imaging studies that stimulation at this location leads to a significant activation of
intracranial structures that are similarly activated by invasive VNS [16]. Only a few randomized controlled trials
have been conducted showing inconsistent results and a large variability in methodology. Nevertheless, there seems
to be a trend toward significant seizure frequency reduction, stimulating further research of this device and the
optimal stimulation parameters [17–19]. This noninvasive approach will be attractive to many patients, although
we can imagine that the lifelong use of an external device may be inconvenient. By combining these devices with
an appropriate biomarker, they could however have an added value, using them as a predictor for the response to
invasive VNS.
We can conclude that there is sufficient evidence demonstrating that VNS is an effective adjunctive treatment for
refractory epilepsy patients not eligible for epilepsy surgery. The efficacy of VNS seems to be comparable to other
neurostimulation modes such as deep brain stimulation of the anterior nucleus of the thalamus and responsive
neurostimulation [20]. However, no head-to-head comparative trials have been conducted to confirm this statement.
Patients considered for neurostimulation should be evaluated according to the proposed prestimulation evaluation
protocol by Carrette et al. to decide on the appropriate type of neurostimulation [20]. The main challenge for VNS
remains identifying responders before patients are implanted. The development of noninvasive VNS devices in
combination with appropriate biomarkers could identify patients who would benefit from VNS therapy and is
therefore gaining scientific interest.
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